NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $705 | +279.0% | 475,000 | +225.3% | 0.00% | – |
Q2 2023 | $186 | +55.0% | 146,000 | +64.0% | 0.00% | – |
Q1 2023 | $120 | -88.9% | 89,000 | -87.0% | 0.00% | – |
Q4 2022 | $1,077 | -99.9% | 685,000 | +31.2% | 0.00% | -100.0% |
Q3 2022 | $731,000 | +18.1% | 522,000 | +12.3% | 0.00% | – |
Q2 2022 | $619,000 | +20.4% | 465,000 | +17.1% | 0.00% | – |
Q1 2022 | $514,000 | -72.1% | 397,000 | -73.3% | 0.00% | – |
Q4 2021 | $1,842,000 | +6251.7% | 1,486,000 | +6654.5% | 0.00% | – |
Q3 2021 | $29,000 | -93.6% | 22,000 | -93.5% | 0.00% | – |
Q2 2021 | $452,000 | +11.6% | 340,000 | +13.7% | 0.00% | – |
Q1 2021 | $405,000 | -83.9% | 299,000 | -83.6% | 0.00% | -100.0% |
Q4 2020 | $2,517,000 | -78.2% | 1,818,000 | -78.3% | 0.00% | -85.7% |
Q3 2020 | $11,543,000 | +420.0% | 8,373,000 | +382.3% | 0.01% | +250.0% |
Q1 2020 | $2,220,000 | +17.5% | 1,736,000 | +26.3% | 0.00% | +100.0% |
Q3 2019 | $1,889,000 | -85.9% | 1,375,000 | -87.7% | 0.00% | -90.0% |
Q4 2018 | $13,392,000 | +108.1% | 11,219,000 | +197.2% | 0.01% | +150.0% |
Q3 2018 | $6,435,000 | +638.0% | 3,775,000 | +525.0% | 0.00% | +300.0% |
Q2 2018 | $872,000 | – | 604,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
III Capital Management | 12,500,000 | $17,262,000 | 3.12% |
CSS LLC/IL | 24,395,000 | $33,616,000 | 1.59% |
Mint Tower Capital Management B.V. | 9,000,000 | $12,407,000 | 1.46% |
Context Partners Fund, L.P. | 3,000,000 | $4,125,000 | 0.90% |
Context Capital Management, LLC | 3,000,000 | $4,125,000 | 0.90% |
SHENKMAN CAPITAL MANAGEMENT INC | 4,258,000 | $5,971,000 | 0.71% |
SSI INVESTMENT MANAGEMENT LLC | 5,888,000 | $8,100,000 | 0.70% |
Aequim Alternative Investments LP | 3,000,000 | $4,155,000 | 0.55% |
WOLVERINE ASSET MANAGEMENT LLC | 32,181,000 | $44,437,000 | 0.40% |
TWO SIGMA SECURITIES, LLC | 13,000,000 | $17,875,000 | 0.36% |